• Proceedings of the Korean Nuclear Society Conference
• /
• 2005.10a
• /
• pp.759-760
• /
• 2005

• Proceedings of the Korean Society of Medical Physics Conference
• /
• 1999.11a
• /
• pp.116-116
• /
• 1999

• Progress in Medical Physics
• /
• v.11 no.2
• /
• pp.131-139
• /
• 2000

We designed high dose rate Ir-192 source which was prepared for substitute the Co-60 source in Ralstron unit (Simatsu, Japan) which is supplied for cervical cancer treatment. The source dimension is 1.5 mm in a diameter and 1.5mm thickness of cylinder and encapsulated with 3 mm diameter of stainless steel(SUS316L) to substituted for the Co-60 source size. The Ir-192 source was prepared the dose model for tissue dose computation through the experimental determination of apparent activity and applied the empirical tissue correction factors extended to 20cm distance. The tissue dose model was applied the 4.69 R/cm-mCi-hr gamma constant and the ratio of energy absorption coefficient of water to that of air showed 1.112 include filteration of the self-absorptions. In this experiments, we prepared the dose computation software to clinical usefulness.

• Progress in Medical Physics
• /
• v.21 no.1
• /
• pp.78-85
• /
• 2010

The compatibility with GammaMed-12i brachytherapy machine for an Ir-192 encapsulated source (IRRS20, KAERI, Korea) manufactured by Korea atomic energy research institute (KAERI) has been investigated. As a mechanical testing of compatibility, precise measurement of step movement with channels, measurement of curvature of radius for wire, and emergency return testing were performed. Periodic measurements of air kerma strength for 45 days were carried out to evaluate decay characteristics of Ir-192 radioisotope and comparison of dose distributions in phantom between KAERI and old sources previously used were performed by film dosimetry. KAERI source has a good compatibility with GammaMed12i machine as a result of mechanical testing. There are in good agreement with calculated values in activity characteristics and there were small differences in dose distributions around the source in comparison between KAERI and old source.

• Korean Journal of Environmental Biology
• /
• v.24 no.4
• /
• pp.387-391
• /
• 2006

Computational and experimental dosimetry of Henschke applicator with respect to high dose rate brachytherapy using the MIRD phantom and a remote control afterloader were performed. A comparison of computational dosimetry was made between the simulated Monte Carlo dosimetry and GAMMADOT brachytherapy Planning system's dosimetry. Dose measurements was performed using ion chamber in a water phantom. Dose rates are calculated using Monte Carlo code MCNP4B and the GAMMADOT. Thecomputational models include the detailed geometry of Ir-192 source, tandem tube, and shielded ovoids for accurate estimation. And transit dose delivered during source extension to and retraction from a given dwell position was estimated by Monte Carlo simulations. Point doses at ICRU bladder/rectal pointswhich have been recommened by ICRU 38 was assessed. Calculated and measured dose distribution data agreed within 4% each other. The shielding effect of ovoids leads to 19% and 20% dose reduction at bladder surface and rectal points.

• Asian Pacific Journal of Cancer Prevention
• /
• v.15 no.20
• /
• pp.8987-8992
• /
• 2014

Background: The efficacy of concurrent chemoradiotherapy in the treatment of locally advanced cervical cancer is well established. We aimed to investigate the long-term efficacy of definitive concurrent chemoradiotherapy for cervical cancer in the University of Malaya Medical Centre. Materials and Methods: A cohort of 60 patients with FIGO stage IB2-IVA cervical cancer who were treated with definitive concurrent chemoradiotherapy with cisplatin followed by intracavitary brachytherapy or external beam radiotherapy (EBRT) boost between November 2001 and May 2008 were analysed. Patients were initially treated with weekly intravenous cisplatin ($40mg/m^2$) concurrent with daily EBRT to pelvis of 45-50Gy followed by low dose rate brachytherapy or EBRT boost to tumour. Local control rate, progression free survival, overall survival and treatment related toxicities graded by the RTOG criteria were evaluated. Results: The mean age was 56. At the median follow-up of 72 months, the estimated 5-year progression-free survival (PFS) (median PFS 39 months) and the 5-year overall survival (OS) (median OS 51 months) were 48% and 50% respectively. The 5-year local control rate was 67.3%. Grade 3-4 late gastrointestinal and genitourinary toxicity occurred in 9.3% of patients. Conclusions: The 5-year PFS and the 5-year OS in this cohort were lower than in other institutions. More advanced stage at presentation, longer overall treatment time (OTT) of more than fifty-six days and lower total dose to point A were the potential factors contributing to a lower survival.

• Asian Pacific Journal of Cancer Prevention
• /
• v.15 no.5
• /
• pp.2217-2220
• /
• 2014

Purpose: To evaluate the survival outcome of early stage endometrioid adenocarcinoma of the endometrium with risk factors for locoregional recurrence treated with combined pelvic external beam radiotherapy (EBRT) and vaginal brachytherapy (VBT) after comprehensive surgery. Materials and Methods: Post-operative radiotherapy by pelvic EBRT and VBT for early stage endometrioid endometrial carcinoma resulted in excellent pelvic control with acceptable complications. This study showed no significant relationships between age, stage, histologic grade and LVSI and overall survival rate. Results: The 5-year overall survival rate (OS) of early stage endometrioid type of endometrial carcinoma was 85.7%. Acute toxicity occurred in 38.1% of the patients, all of whom were grade 1 or 2. Total late toxicity developed in 42.9% of study group, in which 36.99% of them were grade 1-2 and 4.76% were grade 3-4. Conclusions: Post-operative radiotherapy by pelvic EBRT and VBT is acceptable for early stage endometrioid endometrial carcinoma, independent of age, stage, histologic grade and LVSI.

• Progress in Medical Physics
• /
• v.12 no.2
• /
• pp.141-146
• /
• 2001

It is well known that assurance of the radiation therapy needs for an accuracy of $\pm$ 5 % in the delivery of an absorbed dose to target volume. Therefore, the dose evaluation of brachytherapy source and/or linear accelerate beam must be a stability with accuracy. In an advanced country, they recommended to use the radioactive check source for reference air ionization chamber for a stable response of radiation field chamber. In this experiments, the radioactive source Sr-90 and PR-05 air ionization chamber were used for standard source and reference ion chamber. The response of reference ion chamber showed as an 1.000$\pm$ 0.010 uncertainty for 10 years long and the evaliuation f dose discrepancy of clinical field ion chamber showed as 0.997 $\pm$0.011 in a $^{60}$ Co brachytherapy soruce. In our experiments, we can assuarance the long halflife standard source is reliable to preserve the calibration factor of reference chamber in stability.

• Radiation Oncology Journal
• /
• v.9 no.2
• /
• pp.227-232
• /
• 1991

Authors described the remote afterloading endobronchial brachytherapy (EBBT technique using the microSelectron HDR Ir-192 and the Asan Medical Center experience. Total 28 EBBT in 9 patients were performed since November 1989 and 24 EBBT in 8 patients were emploiyed for palliation and 3 EBBT in 1 patient was treated curatively. Authors observed a significant relief of obstructive symptom with tumor regression in 7 patients out of 8 who were treated palliatively but one of them died of pulmonary congestion in 3 weeks after EBBT One patient with prior therapy of extensive electrocautery expired within 1 day after 2nd EBBT procedure with massive hemorrhage from the lesion. EBBT procedure has been tolerable and can be performed as an outpatient.

• Journal of radiological science and technology
• /
• v.45 no.6
• /
• pp.553-560
• /
• 2022

The purpose of this study is to evaluate the clinical risk according to the applicator heterogeneity, mislocation, and tissue heterogeneity correction through a dose verification program during brachytherapy of cervical cancer. We performed image processing with MATLAB on images acquired with CT simulator. The source was modeled and stochiometric calibration and Monte-Carlo algorithm were applied based on dwell time and location to calculate the dose, and the secondary cancer risk was evaluated in the dose verification program. The result calculated by correcting for applicator and tissue heterogeneity showed a maximum dose of about 25% higher. In the bladder, the difference in excess absolute risk according to the heterogeneity correction was not significant. In the rectum, the difference in excess absolute risk was lower than that calculated by correcting applicator and tissue heterogeneity compared to the water-based calculation. In the femur, the water-based calculation result was the lowest, and the result calculated by correcting the applicator and tissue heterogeneity was 10% higher. A maximum of 14% dose difference occurred when the applicator mislocation was 20 mm in the Z-axis. In a future study, it is expected that a system that can independently verify the treatment plan can be developed by automating the interface between the treatment planning system and the dose verification program.